Log In
Print
BCIQ
Print
Print this Print this
 

IPN007

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionHumanized mAb targeting microtubule-associated protein tau (MAPT; tau; FTDP-17)
Molecular Target Microtubule-associated protein tau (tau) (MAPT) (FTDP-17)
Mechanism of Action 
Therapeutic ModalityBiologic
Latest Stage of DevelopmentPreclinical
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$725.0M

$175.0M

$550.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today